modelAminobutyricAcid
Extends from Pharmacolibrary.Drugs.ATC.N.N03AG03.
Information
| name: | AminobutyricAcid | |
| ATC code: | N03AG03 | route: | oral |
| compartments: | 1 | |
| dosage: | 500 | mg |
| volume of distribution: | 0.6 | L |
| clearance: | 8 | L/h |
| other parameters in model implementation | ||
Aminobutyric acid (specifically gamma-aminobutyric acid or GABA) is a non-protein amino acid acting as a major inhibitory neurotransmitter in the mammalian central nervous system. Aminobutyric acid derivatives have been considered for anticonvulsant and anxiolytic activities. The substance corresponding to ATC code N03AG03 is gamma-aminobutyric acid (GABA), but it is not widely approved or used in current clinical practice due to poor blood-brain barrier penetration.
Pharmacokinetics
No human pharmacokinetic models with clinical dosing found published for aminobutyric acid (GABA) as an administered drug. Estimates provided below are based on physicochemical properties and available indirect data.
References
Gould, A, & Amin, S (2024). An overview of ganaxolone as a treatment for seizures associated with cyclin-dependent kinase-like 5 deficiency disorder. Expert review of neurotherapeutics 24(10) 945–951. DOI:10.1080/14737175.2024.2385937 PUBMED:https://pubmed.ncbi.nlm.nih.gov/39082513
Toth, C (2012). Drug safety evaluation of pregabalin. Expert opinion on drug safety 11(3) 487–502. DOI:10.1517/14740338.2012.677026 PUBMED:https://pubmed.ncbi.nlm.nih.gov/22468635
Merlino, G, et al., & Valente, M (2010). Gabapentin enacarbil in restless legs syndrome. Drugs of today (Barcelona, Spain : 1998) 46(1) 3–11. DOI:10.1358/dot.2010.46.1.1424766 PUBMED:https://pubmed.ncbi.nlm.nih.gov/20200691
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
| Pharmacolibrary.Types.TransferRate | ka (from PK_1C_enteral) | 0.016666666666666666 | first order absorption rate |
| Modelica.Units.SI.Time | Tlag (from PK_1C_enteral) | 600 | delay between oral administration and absorption (default 10min) |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)